Intravenous ibandronate in men with osteoporosis: An open pilot study over 2 years

• Published in: Journal of endocrinological investigation Vol. 26; no. 8; pp. 728 - 732
• Main Authors: LAMY, O, SANDINI, L, PACHE, I, FATIO, S, BURNAND, J, BURCKHARDT, P
• Format: Journal Article
• Language: English
• Published: Milano Kurtis 01.08.2003
• Subjects: Adult; Aged; Aged, 80 and over; Biological and medical sciences; Biomarkers; Bone and Bones - metabolism; Bone Density - drug effects; Diphosphonates - administration & dosage; Diphosphonates - adverse effects; Diphosphonates - therapeutic use; Endocrinopathies; Follow-Up Studies; Fractures, Bone - epidemiology; Fundamental and applied biological sciences. Psychology; Humans; Injections, Intravenous; Male; Medical sciences; Middle Aged; Osteoporosis - drug therapy; Osteoporosis - pathology; Pilot Projects; Spine - anatomy & histology; Spine - pathology; Vertebrates: endocrinology; Human; Osteoporosis; Intravenous administration; Diseases of the osteoarticular system; Ibandronic acid; Male; Endocrinology; Public health

In the treatment of osteoporosis, the tolerance of oral bisphosphonates is often low. The high potency of ibandronate allows iv bolus injections that can be repeated every 2 to 3 months. However, the best dose and time interval of the treatment with iv ibandronate is still debated. Efficacy of 2-mg...